| Drug Name: | Darbepoetin alfa (209810-58-2) |
|---|---|
| PubChem ID: | 124040763 |
| SMILES: | CCC1CN2CC[C@@H]1CC2C(C3=C4C=C(C=CC4=NC=C3)OC)OC5=NN=C(C6=CC=CC=C65)OC(C7C[C@H]8CCN7CC8CC)C9=C1C=C(C=CC1=NC=C9)OC |
| InchiKey: | YUCBLVFHJWOYDN-FYEDOUJPSA-N |
| Therapeutic Category: | Hematinics, Hematologic Agents |
| Molecular Weight (dalton) | : | 778.998 |
| LogP | : | 9.2244 |
| Ring Count | : | 6 |
| Hydrogen Bond Acceptor Count | : | 10 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 94.96 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Thalidomide (50-35-1) | Thromboembolic Event | Synergistic | Not understood | Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category